SCHEMBL22197286

SCHEMBL22197286

CCNC(=O)[C@H](C)NC(=O)[C@@H](N)C(C)C

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.48
DPP8 Q6V1X1 2/20 0.48
DPP9 Q86TI2 2/20 0.48
DPP7 Q9UHL4 2/20 0.48
FAP Q12884 1/20 0.48
SLC7A5 Q01650 1/20 0.37
MME P08473 1/20 0.33
ACE P12821 1/20 0.33
CPA1 P15085 1/20 0.33
ACE2 Q9BYF1 1/20 0.33
BACE1 P56817 1/20 0.33
METAP2 P50579 7/20 0.33
METAP1 P53582 6/20 0.33
TSHR P16473 1/20 0.33
CTSC P53634 1/20 0.32
TPSAB1 Q15661 2/20 0.31
PLG P00747 1/20 0.31
PRSS1 P07477 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12257899 0.86 DPP4 (0.47) DPP4DPP8DPP9DPP7FAP
SCHEMBL17832776 0.86 DPP4 (0.47) DPP4DPP8DPP9DPP7FAP
SCHEMBL8265865 0.86 DPP4 (0.47) DPP4DPP8DPP9DPP7FAP
SCHEMBL24648735 0.85 DPP7 (0.47) DPP4DPP8DPP9DPP7FAP
SCHEMBL10954323 0.84 DPP4 (0.45) DPP4DPP8DPP7MMEACE
SCHEMBL24648940 0.83 DPP4 (0.47) DPP4DPP8DPP9DPP7FAP
Bromide SCHEMBL11517257 0.82 DPP4 (0.44) DPP4DPP8DPP7MMEACE
SCHEMBL10954147 0.82 DPP4 (0.44) DPP4DPP8DPP7MMEACE
SCHEMBL24648936 0.82 DPP4 (0.43) DPP4DPP8DPP9DPP7FAP
SCHEMBL29589429 0.81 ALDH1A1 (0.48) DPP4DPP8DPP9DPP7FAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020254612-A1 CONTROLLED-RELEASE TYROSINE KINASE INHIBITOR COMPOUNDS WITH LOCALIZED PD PROPERTIES Ascendis Pharma Oncology Division A/S (DK) 2020-12-24 WO disclosed
WO-2020254613-A1 CONTROLLED-RELEASE TYROSINE KINASE INHIBITOR COMPOUNDS WITH LOCALIZED PK PROPERTIES Ascendis Pharma Oncology Division A/S (DK) 2020-12-24 WO disclosed
WO-2020254617-A1 ANTI-CTLA4 COMPOUNDS WITH LOCALIZED PK PROPERTIES Ascendis Pharma Oncology Division A/S (DK) 2020-12-24 WO disclosed
WO-2020254607-A1 ANTI-CTLA4 COMPOUNDS WITH LOCALIZED PD PROPERTIES Ascendis Pharma Oncology Division A/S (DK) 2020-12-24 WO disclosed
WO-2020254609-A1 TYROSINE KINASE INHIBITOR CONJUGATES Ascendis Pharma Oncology Division A/S (DK) 2020-12-24 WO disclosed
WO-2020254611-A1 ANTI-CTLA4 CONJUGATES Ascendis Pharma Oncology Division A/S (DK) 2020-12-24 WO disclosed
WO-2020141223-A1 INDUCTION OF SUSTAINED LOCAL INFLAMMATION ASCENDIS PHARMA A/S (DK) 2020-07-09 WO disclosed
WO-2020141221-A1 CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS ASCENDIS PHARMA A/S (DK) 2020-07-09 WO disclosed
WO-2020141225-A1 MINIMIZATION OF SYSTEMIC INFLAMMATION ASCENDIS PHARMA A/S (DK) 2020-07-09 WO disclosed